LKFT vs SNY
Lakefront Biotherapeutics NV and Sanofi, side by side — 10 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | LKFT | SNY |
|---|---|---|
| Revenue | €1.1B | €43.6B |
| Net income | €320.9M | €7.8B |
| Gross margin | 97.3% | 77.2% |
| Net margin | 28.9% | 18.0% |
| Return on equity | 10.5% | 10.5% |
| Diluted EPS | €4.87 | €6.37 |
| Dividend / share | · | €3.92 |
| Payout ratio | · | 61.1% |
| Free cash flow | €-271.2M | · |
| Equity | · | €71.4B |
| Net debt / equity | · | 0.15× |
| Current ratio | 20.15× | 1.09× |
| Revenue CAGR 5y | 18.4% | 3.9% |
| Profit CAGR 5y | · | −8.7% |
SNY bills 39.2× the revenue of LKFT, and LKFT keeps more of each dollar of revenue as profit (28.9% against 18.0%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | LKFT | SNY |
|---|---|---|
| FY2025 | €1.1B | €43.6B |
| FY2024 | €275.6M | €41.1B |
| FY2023 | €239.7M | €37.8B |
| FY2022 | €241.2M | €37.7B |
| FY2021 | €234.4M | €37.8B |
| FY2020 | €478.1M | €36.0B |
| FY2019 | €834.9M | €36.1B |
| FY2018 | €278.7M | €34.5B |
| FY2017 | €127.1M | €35.1B |
| FY2016 | €129.5M | €33.8B |
Bottom line
| Fiscal year | LKFT | SNY |
|---|---|---|
| FY2025 | €320.9M | €7.8B |
| FY2024 | €74.1M | €5.6B |
| FY2023 | €211.7M | €5.4B |
| FY2022 | €-218.0M | €8.4B |
| FY2021 | €-103.2M | €6.2B |
| FY2020 | €-305.4M | €12.3B |
| FY2019 | €149.8M | €2.8B |
| FY2018 | €-29.3M | €4.3B |
| FY2017 | €-115.7M | €8.4B |
| FY2016 | €54.0M | €4.7B |
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −€42,513,752,000 | SNY |
| FY2024 | −€40,805,351,000 | SNY |
| FY2023 | −€37,577,276,000 | SNY |
| FY2022 | −€37,409,751,000 | SNY |
| FY2021 | −€37,526,616,000 | SNY |
| FY2020 | −€35,562,947,000 | SNY |
| FY2019 | −€35,291,099,000 | SNY |
| FY2018 | −€34,184,334,000 | SNY |
| FY2017 | −€34,944,913,000 | SNY |
| FY2016 | −€33,679,481,000 | SNY |
| FY2015 | −€34,020,437,000 | SNY |
SNY has reported the higher revenue in every one of these 11 fiscal years. The gap has widened since the earliest year compared.
11 of 11 comparable fiscal years — a year missing data on either side is not counted.
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +10.9 pp | LKFT |
| FY2024 | +13.2 pp | LKFT |
| FY2023 | +73.9 pp | LKFT |
| FY2022 | −112.9 pp | SNY |
| FY2021 | −60.7 pp | SNY |
| FY2020 | −98.1 pp | SNY |
| FY2019 | +10.2 pp | LKFT |
| FY2018 | −23.3 pp | SNY |
| FY2017 | −115.4 pp | SNY |
| FY2016 | +27.5 pp | LKFT |
| FY2015 | −312.2 pp | SNY |
The higher net margin has changed hands between LKFT and SNY over this period.
11 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
LKFT's net margin has been more volatile than SNY's over the 11 comparable fiscal years — 99.7 percentage points of standard deviation against 6.9.
11 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between LKFT and SNY over these 11 fiscal years — LKFT led in 5 and SNY in 6.
11 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
LKFT's return on equity has been more volatile than SNY's over the 11 comparable fiscal years — 12.3 percentage points of standard deviation against 4.1.
11 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between LKFT and SNY over these 11 fiscal years — LKFT led in 3 and SNY in 8.
11 of 11 comparable fiscal years — a year missing data on either side is not counted.